Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

747 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Selle F, Sevin E, Ray-Coquard I, Mari V, Berton-Rigaud D, Favier L, Fabbro M, Lesoin A, Lortholary A, Pujade-Lauraine E. Selle F, et al. Among authors: fabbro m. Ann Oncol. 2014 Nov;25(11):2191-2196. doi: 10.1093/annonc/mdu392. Epub 2014 Sep 10. Ann Oncol. 2014. PMID: 25210017 Free article. Clinical Trial.
High dose chemotherapy in ovarian cancer.
Pujade-Lauraine E, Curé H, Battista C, Guastalla JP, Chiurazzi B, Fabbro M, Tubiana-Mathieu N, Bourgeois H, Lioure B, Paraiso D, Lotz JP. Pujade-Lauraine E, et al. Among authors: fabbro m. Int J Gynecol Cancer. 2001;11 Suppl 1:64-7. doi: 10.1046/j.1525-1438.2001.11(suppl.1)sup1064.x. Int J Gynecol Cancer. 2001. PMID: 11489006 Review. No abstract available.
Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
Lotz JP, Pautier P, Selle F, Viens P, Fabbro M, Lokiec F, Viret F, Gligorov J, Gosse B, Provent S, Ribrag V, Micléa JM, Dosquet C, Goetschel A, Cailliot C, Lefèvre G, Genève J, Lhommé C; Groupe d' Intensification des traitements des Tumeurs Ovariennes (ITOV Group). Lotz JP, et al. Among authors: fabbro m. Bone Marrow Transplant. 2006 Apr;37(7):669-75. doi: 10.1038/sj.bmt.1705310. Bone Marrow Transplant. 2006. PMID: 16501591 Clinical Trial.
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.
Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V, Buyse M. Piedbois P, et al. Among authors: fabbro m. Ann Oncol. 2007 Jan;18(1):52-57. doi: 10.1093/annonc/mdl355. Epub 2006 Oct 17. Ann Oncol. 2007. PMID: 17047001 Free article. Clinical Trial.
747 results